Adjuvant Melanoma Therapy - Head-Spinning Progress.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Complexities in supportive care for people with metastatic breast cancer: a qualitative study.Journal of cancer survivorship : research and practice · 2026
   Article
2. Professionally led support groups for people living with advanced or metastatic cancer: a systematic scoping review of effectiveness and factors critical to implementation success within real-world healthcare and community settings.Journal of cancer survivorship : research and practice · 2025
   Article
3. The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.Frontiers in oncology · 2024
   Review
4. CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma.Cancers · 2021
   Article
5. Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina.Oncology and therapy · 2021
   Article
6. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.Clinical drug investigation · 2020
   Article
7. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study.BMJ open · 2020
   Article
8. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.Neurosurgery · 2019
   Article
9. Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation.Scientific reports · 2019
   Article
10. The evolving role of immuno-oncology for the treatment of head and neck cancer.Laryngoscope investigative otolaryngology · 2019
    Review

Corrections and comments

• Comment on
  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.2017
• Comment on
  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as